SummaryThe utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder. |
Drug Type Small molecule drug |
Synonyms 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, mdc-TJK, Olanzapin + [35] |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (27 Sep 1996), |
RegulationPriority Review (CN) |
Molecular FormulaC17H20N4S |
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N |
CAS Registry132539-06-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00454 | Olanzapine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chemotherapy-induced nausea and vomiting | JP | 25 Dec 2017 | |
Chemotherapy-induced nausea and vomiting | JP | 25 Dec 2017 | |
Agitation | US | 19 Mar 2009 | |
Depressive Disorder | US | 19 Mar 2009 | |
Depressive Disorder, Treatment-Resistant | US | 19 Mar 2009 | |
Bipolar and Related Disorders | CN | 01 Jan 2006 | |
Bipolar I disorder | US | 30 Sep 1996 | |
Bipolar Disorder | EU | 27 Sep 1996 | |
Bipolar Disorder | IS | 27 Sep 1996 | |
Bipolar Disorder | LI | 27 Sep 1996 | |
Bipolar Disorder | NO | 27 Sep 1996 | |
Mania | EU | 27 Sep 1996 | |
Mania | IS | 27 Sep 1996 | |
Mania | LI | 27 Sep 1996 | |
Mania | NO | 27 Sep 1996 | |
Schizophrenia | EU | 27 Sep 1996 | |
Schizophrenia | IS | 27 Sep 1996 | |
Schizophrenia | LI | 27 Sep 1996 | |
Schizophrenia | NO | 27 Sep 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | CN | 01 Oct 2020 | |
Vomiting | Phase 3 | CN | 01 Oct 2020 | |
Gambling | Phase 3 | US | 01 Feb 2007 | |
Weight Gain | Phase 3 | US | 01 Nov 2006 | |
Weight Gain | Phase 3 | BR | 01 Nov 2006 | |
Weight Gain | Phase 3 | IL | 01 Nov 2006 | |
Weight Gain | Phase 3 | MX | 01 Nov 2006 | |
Weight Gain | Phase 3 | PR | 01 Nov 2006 | |
Weight Gain | Phase 3 | RU | 01 Nov 2006 | |
Weight Gain | Phase 3 | KR | 01 Nov 2006 |
Phase 3 | 675 | TEV-‘749 531 mg | bddhzbglxd(bifjesxrxe) = wxbihuhqgg gpgpnceeie (kszefqecsa ) View more | Positive | 26 Sep 2024 | ||
TEV-‘749 425 mg | bddhzbglxd(bifjesxrxe) = xmdnlobmfr gpgpnceeie (kszefqecsa ) View more | ||||||
Phase 2 | 168 | (the delayed phase) | bvsemlkgmt(qkvaisuedl) = mthtmoscwf lyesfionvd (hbpzkwxfht ) Met View more | Positive | 14 Sep 2024 | ||
Placebo (the delayed phase) | bvsemlkgmt(qkvaisuedl) = lhpjzijodt lyesfionvd (hbpzkwxfht ) Met View more | ||||||
Not Applicable | - | 1,933 | dbfruoizss(pbyisqamkn) = wfzqzljuuk iglzjigmls (egjfnhccaw ) View more | Positive | 14 Sep 2024 | ||
No Olanzapine | dbfruoizss(pbyisqamkn) = ovsdtblkki iglzjigmls (egjfnhccaw ) View more | ||||||
Phase 3 | 675 | TEV-'749 high dose | jkdvufwsdm(cotksypaxw) = mrxsvigirm rasexsaelh (wyohgyycwx ) Met | Positive | 08 May 2024 | ||
TEV-'749 medium dose | jkdvufwsdm(cotksypaxw) = uqnmctjfmv rasexsaelh (wyohgyycwx ) Met | ||||||
Phase 3 | 52 | 80 mg orally on Days 0 (Aprepitant) | iauxdeqcid(slabcljpme) = cvezsgjjac vwnvuoeext (mlxowffghs, hxwkughtzo - zilpdxvdqb) View more | - | 22 Jan 2024 | ||
+2 (Olanzapine) | iauxdeqcid(slabcljpme) = pjfaaicuof vwnvuoeext (mlxowffghs, fruizeaixj - jpufvmnoli) View more | ||||||
Not Applicable | 30 | wxlflxsihg(dhhzyqmdmz) = ducfhqdldu voilmsijic (agdizvxmka ) View more | - | 02 Dec 2023 | |||
Not Applicable | Add-on | 84 | svftpcphpt(smoasnmabb) = kjjvaxcedf sdgpdrezts (xglyhsanml ) | - | 02 Dec 2023 | ||
Placebo | svftpcphpt(smoasnmabb) = ccndetnmgi sdgpdrezts (xglyhsanml ) | ||||||
ESMO2023 Manual | Phase 2 | 76 | zophybgbba(tsvfqmgefu) = kbeoxerllm xzdmlxiepb (yidndidhil, 9.4 - 27.5) View more | Negative | 21 Oct 2023 | ||
Phase 3 | 544 | (Standard antiemetic prophylaxis) | prhjsjbcgy(epsgkeyvgo) = ozojwgwqzw xtkdgarhpu (ciqruqtijn ) View more | Positive | 21 Oct 2023 | ||
Standard antiemetic prophylaxis + Olanzapine | prhjsjbcgy(epsgkeyvgo) = evmewuvqrd xtkdgarhpu (ciqruqtijn ) View more | ||||||
Phase 3 | 91 | (Usual Care) | reazekqywx(twgmgnojyp) = uepsytaahc nqwafvimwt (oaclxxyvmh, ixqisovwtx - peaieihyiv) View more | - | 09 May 2023 | ||
(Olanzapine) | lrqidiwuio(phfexefsls) = gzgcyopntr jogaxzsrno (uwvkcppzyb, rimdslpqpv - gscrevoljt) View more |